Zika Infection in Third Trimester May Not Harm Development

This article originally appeared here.
Share this content:
Zika Infection in Third Trimester May Not Harm Development
Zika Infection in Third Trimester May Not Harm Development

THURSDAY, June 16, 2016 (HealthDay News) -- The danger of Zika-related birth defects may be confined to maternal infections that occur during the first two trimesters of pregnancy, according to a study led by Margaret Honein, Ph.D., of the U.S. Centers for Disease Control and Prevention, and published online June 15 in the New England Journal of Medicine.

Colombian and U.S. researchers studied 11,944 pregnancies occurring in 2015 among women in Colombia, a country that is endemic for the mosquito that spreads the Zika virus.

The study detected no cases of infant abnormalities among women who contracted Zika during the last three months of their pregnancy, the researchers said. They stressed that at the time of the study's publication, 10 percent of the 1,850 women infected late in pregnancy had not yet given birth, therefore the data remain incomplete and preliminary.

Still, data on the other 90 percent of women suggest that "maternal infection with the Zika virus during the third trimester of pregnancy is not linked to structural abnormalities in the fetus," the researchers concluded.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »